Is galectin-3 a promoter of ventricular dysfunction?
Heart failure is nowadays a common condition associated with high mortality and increased healthcare-related costs. Over the years, the research on heart failure management has been extensive in order to better diagnose and treat the condition. Since the progression of left ventricular dysfunction i...
Main Authors: | Lupu Adrian, Lupu Silvia, Agoston-Coldea Lucia |
---|---|
Format: | Article |
Language: | English |
Published: |
Sciendo
2018-01-01
|
Series: | Romanian Journal of Laboratory Medicine |
Subjects: | |
Online Access: | https://doi.org/10.2478/rrlm-2018-0001 |
Similar Items
-
The Role of Galectin-3 in Predicting Congenital Heart Disease Outcome: A Review of the Literature
by: Amalia Făgărășan, et al.
Published: (2023-06-01) -
Perindopril and a Galectin-3 Inhibitor Improve Ischemic Heart Failure in Rabbits by Reducing Gal-3 Expression and Myocardial Fibrosis
by: Sha Li, et al.
Published: (2019-03-01) -
Reversibility of ventricular dysfunction: clinical experience in a medical office
by: Antonio Carlos Pereira Barretto
Published: (2001-12-01) -
Features in the Processes of Left Ventricular Remodeling Depending on the Degree of Renal Dysfunction in Patients with Chronic Heart Failure
by: Umida Kamilova, et al.
Published: (2022-06-01) -
Circulating troponin and further left ventricular ejection fraction improvement in patients with previously recovered left ventricular ejection fraction
by: Jonathan G. Howlett, et al.
Published: (2020-10-01)